Humacyte (HUMA) Notes Payables (2020 - 2021)
Humacyte's (HUMA) quarterly Notes Payables came in at $10000.0 in Q1 2021, down 89.49% quarter-over-quarter from $95136.0 in Q4 2020.
Powered by 
Analysis
Humacyte (HUMA) Notes Payables (2020 - 2021) Analysis & Trends
Humacyte (HUMA) has reported Notes Payables for 2 consecutive years, with $10000.0 the latest figure, recorded in Q1 2021.
- On a quarterly basis, Notes Payables changed N/A year-over-year to $10000.0 in Q1 2021; TTM through Mar 2021 was $10000.0, a N/A change from a year earlier, with the FY2020 full-year figure at $95136.0, changed N/A from the prior year.
- Notes Payables was $10000.0 for Q1 2021 at Humacyte, down from $95136.0 in the prior quarter.
- Over five years, Notes Payables peaked at $95136.0 in Q4 2020 and troughed at $10000.0 in Q1 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.36 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.03 Bn | 5.03 Bn | - |
| 3 | Iovance Biotherapeutics | 3.64 Bn | 3.35 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.54 Bn | 2.58 Bn | 251.50 Mn |
| 5 | uniQure | 2.98 Bn | 2.98 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.53 Bn | 2.53 Bn | - |
| 7 | Precigen | 2.40 Bn | 2.40 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.15 Bn | 1.36 Bn | 251.87 Mn |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn |
| 10 | Humacyte | 133.67 Mn | 133.67 Mn | -825,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2021 | 10,000.00 |
| Dec 31, 2020 | 95,136.00 |
| Sep 30, 2020 | 89,076.00 |